 |
Acorda Therapeutics announced positive results of a Phase 3, controlled clinical trial of Fampridine-SR, an oral drug designed to provide symptomatic relief by compensating for lost nerve conduction. The placebo-controlled study involved 301 patients with all types of multiple sclerosis at 33 sites in the US and Canada. The primary outcome measured was improvement in the time it took to walk 25 feet.
According to the company, those on active treatment showed an average increase in walking speed of 25 percent versus those on inactive placebo.
The company is expected to meet with the US Food and Drug Administration to determine next steps needed to apply for marketing approval. It is not yet clear whether an additional clinical trial will be required.
For more information, please click on the link below.
Source: US National MS Society
Weblink: click here
|
